Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

3.1K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.9K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.9K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.6K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.6K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

5.7K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.7K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.7K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.7K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathophysiology of Ketoacidosis: Core Curriculum 2026.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

The Sexual Dimorphism in Kidney Potassium Handling: A Conceptual Review.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Real-World Insights on Attitudes and Treatment of Hyperkalemia.

Mayo Clinic proceedings·2026
Same author

Sodium reduction and salt substitutes: impact on blood pressure and recurrent stroke.

Current opinion in cardiology·2026
Same author

Systemic effects of metabolic acidosis.

Clinical nephrology·2026
Same author

ASN Kidney Health Guidance on Potassium and Phosphorus Food Additives.

Journal of the American Society of Nephrology : JASN·2025
Same journal

Neural Control of Tissue Perfusion: Emerging Evidence and Beyond.

Current hypertension reports·2026
Same journal

Correction to: Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
Same journal

Intersection of Pediatric Hypertension and Cardiovascular-Kidney-Metabolic Disease.

Current hypertension reports·2026
Same journal

Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?

Current hypertension reports·2026
Same journal

Leveraging the Electronic Health Record to Identify and Manage Resistant Hypertension.

Current hypertension reports·2026
Same journal

Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
See all related articles

Related Experiment Video

Updated: Apr 18, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.4K

Vasopressin receptor antagonists.

Biff F Palmer1

  • 1Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390, USA, biff.palmer@utsouthwestern.edu.

Current Hypertension Reports
|January 22, 2015
PubMed
Summary
This summary is machine-generated.

Arginine vasopressin (AVP) regulates body fluid tonicity and influences metabolism, cardiovascular function, bone health, and cognition. AVP receptor antagonists, approved for hyponatremia, show promise for other conditions.

More Related Videos

Culturing Primary Rat Inner Medullary Collecting Duct Cells
06:11

Culturing Primary Rat Inner Medullary Collecting Duct Cells

Published on: June 21, 2013

15.3K
Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
12:19

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli

Published on: June 27, 2015

11.7K

Related Experiment Videos

Last Updated: Apr 18, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.4K
Culturing Primary Rat Inner Medullary Collecting Duct Cells
06:11

Culturing Primary Rat Inner Medullary Collecting Duct Cells

Published on: June 21, 2013

15.3K
Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
12:19

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli

Published on: June 27, 2015

11.7K

Area of Science:

  • Endocrinology
  • Pharmacology
  • Physiology

Background:

  • Arginine vasopressin (AVP) is crucial for fluid balance.
  • AVP also impacts glucose metabolism, cardiovascular homeostasis, bone health, and cognitive functions.
  • AVP receptor antagonists are approved for treating hyponatremia.

Purpose of the Study:

  • To review the expanding applications of AVP receptor antagonists.
  • To explore potential new disease states treatable with these antagonists.

Main Methods:

  • Literature review of AVP's diverse physiological roles.
  • Analysis of current and emerging therapeutic uses of AVP receptor antagonists.

Main Results:

  • AVP antagonists are effective in hyponatremia treatment.
  • Emerging research suggests AVP's involvement in other conditions.
  • Further investigation into AVP antagonism is warranted for broader therapeutic benefits.

Conclusions:

  • AVP receptor antagonists have a growing therapeutic potential beyond hyponatremia.
  • Targeting AVP pathways may offer new treatment strategies for various diseases.